All In Biotech

Drug Trial Radar · NCT07439510

A Study to Investigate the Effects and Safety of Codabakalner for the Treatment of FXS in Male Participants and Adult Participants With ADS

A Phase 2b/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Codabakalner in Male Participants With Full Mutation Fragile X Syndrome and Adult Participants With Autism Spectrum Disorders

Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Dec 1, 2026

Primary completion

Feb 1, 2030

Study completion Jun 30, 2030

Sponsor

Lead sponsor
SpinogenixIndustry
Sponsor type
Industry
First posted
Feb 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Study to Investigate the Effects and Safety of Codabakalner for the Treatment of Fragile X Syndrome in Male Participants and Adult Participants with Autism Spectrum Disorders

Conditions

  • Fragile X Syndrome (FXS)
  • Autism Spectrum Disorder (ASD)

Interventions

  • CodabakalnerDrug

    synthetic small molecule

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 2b: FXS- Change from baseline in Total Cognition Composite Change Sensitive Score from the NIH-TCBTime frame: 28 days
  2. Phase 2b: ASD - Change from Baseline at Day 28 on the Vineland Adaptive Behavior Scales in ASD(Vineland-III) Adaptive Behavior Composite ScoreTime frame: 28 days
  3. Phase 3: FXS - Change from baseline in Total Cognition Composite score from the NIH-TCBTime frame: 12 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.